ReWalk机器人技术 RWLK 深 沪
等待开盘 11-19 09:30:00 美东时间
1.0501
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.0501
- 总市值 6293.98万
- 52周最高 9.10
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 3.9228
- 委 比 0.00%
- 总股本 5993.70万
- 历史最高 7648.55
- 量 比 0
- 振 幅 0.00%
- 历史最低 2.87
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lifeward Gets First Prior Authorization From UnitedHealthcare Medicare Advantage Plan For ReWalk 7 Personal Exoskeleton
Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that it received
11-17 21:05
Lifeward to Report Third Quarter Financial Results on November 14, 2025
<p>Lifeward Ltd. announced it will release its third quarter 2025 financial results on November 14, 2025, prior to market open. A conference call and webcast will be hosted by Mark Grant and Almog Adar at 8:30 a.m. EST to discuss the results. Access details, including toll-free numbers and an access code, are provided. The webcast will also be archived on the company’s website. Lifeward designs innovative medical technologies to improve the lives...
11-10 12:00
First Commercial Medicare Advantage Plan Provides Payment for ReWalk 7 Personal Exoskeleton
Lifeward Ltd. announced its first payment from a commercial Medicare Advantage Plan for its ReWalk 7 Personal Exoskeleton. The company reported accelerated claim approval timelines, with most Medicare claims processed in 30-60 days. CMS finalized a Medicare reimbursement pathway for personal exoskeletons in 2024, leading to faster processing and reduced appeals.
09-09 12:30
Lifeward Receives CE Mark For ReWalk 7 Exoskeleton; Expands Commercial Sales In Europe
Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, announced today that the company
09-08 20:34
Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton
<p>Lifeward Ltd. has received CE mark approval for the ReWalk 7 Personal Exoskeleton, authorizing its commercial sale in Europe. The seventh-generation device features innovations like cloud connectivity, push-button control, customizable walking speeds, and stair/curb activation. Europe represents 40% of Lifeward's exoskeleton sales, predominantly through Lifeward GmbH in Germany, where reimbursement processes are established. CEO Mark Grant hig...
09-08 12:30
Administrative Law Judge Determines ReWalk Personal Exoskeleton is “Reasonable and Necessary” for Medicare Beneficiary
A recent ruling by an Administrative Law Judge (ALJ) has determined that the ReWalk Exoskeleton, developed by Lifeward Ltd., is a "reasonable and necessary" medical device for individuals with spinal cord injuries (SCI), allowing Medicare coverage for its use. This decision, which supports the medical necessity of the device, follows an April 2024 CMS ruling to finalize Medicare reimbursement for personal exoskeletons. The ReWalk Exoskeleton enab...
06-24 20:05
InspireMD appoints Michael Lawless CFO
InspireMD (NASDAQ:NSPR) announced on Tuesday the appointment of Michael Lawless as CFO, effective on or before June 30. Lawless is set to succeed Craig Shore. Most recently, Lawless served as the CFO ...
06-04 04:33
Lifeward appoints Mark Grant as CEO
Lifeward (NASDAQ:LFWD) announced on Monday that Mark Grant has been appointed as the company’s new president and chief executive officer, effective June 2, 2025. Larry Jasinski, Lifeward’s outgoing CE...
05-19 21:03
Lifeward Announces The U.S. National Launch Of The Rewalk 7 Personal Exoskeleton
Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal cord injuryNew and improved features streamline user experience for greater control, engagement, and
04-15 20:17
What's Going On With Lifeward Shares Thursday?
Lifeward stock is trading higher on Thursday after the company announced that its ReWalk 7 received 510(k) clearance from the Food and Drug Administration (FDA).
03-13 23:30
